Adenocarcinoma of the Pancreas Recruiting Phase 1 Trials for Gemcitabine (DB00441)

Also known as: Pancreatic adenocarcinoma / Adenocarcinoma Pancreas / Pancreas, Adenocarcinoma / Pancreas Adenocarcinoma / Adenocarcinoma of Pancreas / Adenocarcinoma, Pancreas

IndicationStatusPhase
DBCOND0029532 (Adenocarcinoma of the Pancreas)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02707328Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)Treatment
NCT02336087Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by SurgeryTreatment
NCT03703089Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal CytologyTreatment
NCT02349867Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic CancerTreatment
NCT03703063Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic CancerTreatment
NCT02495896Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid TumorsTreatment
NCT03307148Stromal TARgeting for PAncreatic Cancer (STAR_PAC)Treatment